%0 Journal Article %T Experiences of Thrombolytic Therapy for Ischemic Stroke in Tuzla Canton, Bosnia and Herzegovina %A D£¿evdet Smajlovi£¿ %A Denisa Salihovi£¿ %A Omer £¿. Ibrahimagi£¿ %A Zikrija Dostovi£¿ %A Leila Avdi£¿ %A Mirjana Vidovi£¿ %J ISRN Stroke %D 2014 %R 10.1155/2014/313976 %X Aim. To demonstrate our experiences of thrombolytic therapy in acute ischemic stroke. Subjects and Methods. Patients with ischemic stroke treated with rt-PA, admitted at the Department of Neurology, Tuzla, Bosnia and Herzegovina, in the period between April 1, 2008, and December 31, 2012, were included. Results. Between April 2008 and December 2012, intravenous rt-PA was given to 87 patients with acute ischemic stroke, which represents 3.2% of patients with acute ischemic stroke admitted to our department in that period. Hypertension was the leading stroke risk factor. The mean NIHSS score before thrombolysis was 12 (range 4¨C21). Large artery arteriosclerosis was the most common stroke etiology. The mean door-to-needle time was 72 minutes and onset-to-needle time 152 minutes. Half of patients (44/87) had a significant improvement within the first 24 hours. Parenchymal hemorrhage occurred in 5 patients (6%) and was fatal in two cases. At 3-month follow-up, 45% of patients (39/87) had good outcome (mRS 0 or 1). Sixteen patients were dead at 3 months, and mean baseline stroke severity was significantly higher in patients who died (NIHSS 16.5 versus 11, ). Conclusion. The number of patients with acute ischemic stroke treated using rt-PA in the Department of Neurology, Tuzla, is lower than in developed countries. Thrombolytic therapy is safe and leads to favorable outcome in half of the patients. 1. Introduction Thromboembolic occlusion of an artery leading to the brain or in the brain is a major cause of ischemic stroke. The size and site of the occlusion and the efficiency of compensatory flow through collateral arteries determine the amplitude and extension of the drop in the blood flow. Reperfusion should be done as early as possible to avoid cerebral lesion and complications caused by ischemic injury to the blood vessel walls and blood-brain barrier. Thrombolysis with intravenous recombinant tissue plasminogen activator (rt-PA) is the first evidence based treatment for acute ischemic stroke, which aims to reduce the cerebrovascular lesion. Intravenous rt-PA given within 3¨C4.5 hours after the onset of acute ischemic stroke in the territory of the middle cerebral artery significantly increases the proportion of patients left without handicap and without dependency after 3 months [1]. In the European Union, rt-PA was approved in 2002 and has been used widely since then [2, 3]. We present our results of thrombolytic therapy in acute ischemic stroke reffering to demographic information, time parameters, and clinical outcome. 2. Subjects and Methods Patients %U http://www.hindawi.com/journals/isrn.stroke/2014/313976/